These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Stuerenburg HJ, Petersen K, Bäumer T, Rosenkranz M, Buhmann C, Thomasius R. Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289 [Abstract] [Full Text] [Related]
3. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users. Parrott A. Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401 [No Abstract] [Full Text] [Related]
4. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. de Sola Llopis S, Miguelez-Pan M, Peña-Casanova J, Poudevida S, Farré M, Pacifici R, Böhm P, Abanades S, Verdejo García A, Langohr K, Zuccaro P, de la Torre R. J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910 [Abstract] [Full Text] [Related]
7. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Gouzoulis-Mayfrank E, Daumann J. Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508 [Abstract] [Full Text] [Related]